Connect with us

Health

Edison Releases Update On GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

Published

on

GW Pharmaceuticals PLC- ADR

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) recently reported that a rolling NDA submission for Epidiolex in both Lennox-Gastaut syndrome and Dravet syndrome is underway. The pre-clinical plan has already been filed, the clinical module is in course, and the firm anticipates to close the chemistry, manufacturing and controls segment in October.

The company projects the FDA will allow priority review designation, which would allow a PDUFA date in June 2018. In Europe, pre-submission talks were closed with the EMA and the agency accepted that the firm can submit for approval for LGS and Dravet in a single application. An EMA submission is projected in Q417.

The highlights

GW Pharmaceuticals has lowered its valuation from $3.43 billion, or $136.08 per ADS, to $3.14 billion, or $124.24 a ADS. This is primarily due to lowering Sativex projections, increasing operating spending projections, as well as factoring in the NDA filing delay. The company now anticipate profitability in 2020 with a total cash burn of about $325 million until then. It is projected that GW Pharmaceuticals has adequate cash to achieve its objectives without additional capital.

Edison comes in the leading list of investment research and advisory firm, with offices in North America, the Middle East, Asia Pacific and Europe. The heart of Edison is their world-popular equity research platform and extensive multi-sector expertise. At Edison, the research is mainly read by global investors, stakeholders and advisers. Edison Advisors leverages company’s core research platform to offer differentiated services including strategic consulting and investor relations.

Edison is regulated and authorized by the Financial Conduct Authority. It is not a broker-dealer or adviser and does not offer investment advice. The reports offered by Edison are not solicitations to sell or buy any securities. Hence, any decision to buy or sell the securities should be carefully deliberated by the investors.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement